Details of the Drug

General Information of Drug (ID: DM96SE0)

Drug Name
Haloperidol
Synonyms
Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 375.9
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.8 mL/min/kg [5]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.57 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.08% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 17 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.037 mg/mL [3]
Chemical Identifiers
Formula
C21H23ClFNO2
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
Canonical SMILES
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChIKey
LNEPOXFFQSENCJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3559
ChEBI ID
CHEBI:5613
CAS Number
52-86-8
DrugBank ID
DB00502
TTD ID
D0D1AL
VARIDT ID
DR00426
INTEDE ID
DR0801
ACDINA ID
D00310

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 6.83E-06 -1.42E-01 -4.93E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Haloperidol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Haloperidol and Quetiapine. Schizophrenia [6A20] [98]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Haloperidol and Mesoridazine. Schizophrenia [6A20] [98]
Thioridazine DM35M8J Major Decreased metabolism of Haloperidol caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [99]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Haloperidol and Aripiprazole. Schizophrenia [6A20] [100]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Haloperidol and Iloperidone. Schizophrenia [6A20] [98]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Haloperidol and Paliperidone. Schizophrenia [6A20] [98]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Haloperidol and Molindone. Schizophrenia [6A20] [100]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Haloperidol and Thiothixene. Schizophrenia [6A20] [100]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Haloperidol and Trifluoperazine. Schizophrenia [6A20] [98]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Haloperidol and Risperidone. Schizophrenia [6A20] [98]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Haloperidol and Amisulpride. Schizophrenia [6A20] [98]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Haloperidol and Asenapine. Schizophrenia [6A20] [98]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Haloperidol and Pimozide. Schizophrenia [6A20] [101]
⏷ Show the Full List of 13 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Haloperidol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Haloperidol and Ivosidenib. Acute myeloid leukaemia [2A60] [102]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Haloperidol and Midostaurin. Acute myeloid leukaemia [2A60] [98]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Haloperidol and Idarubicin. Acute myeloid leukaemia [2A60] [98]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Haloperidol and Daunorubicin. Acute myeloid leukaemia [2A60] [98]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Haloperidol and Oliceridine. Acute pain [MG31] [103]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Haloperidol and Scopolamine. Addictive disorder [6C50-6C5Z] [100]
Mitotane DMU1GX0 Major Increased metabolism of Haloperidol caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [104]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Haloperidol and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [105]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Haloperidol and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [105]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Haloperidol and Memantine. Alzheimer disease [8A20] [100]
Rivastigmine DMG629M Moderate Antagonize the effect of Haloperidol when combined with Rivastigmine. Alzheimer disease [8A20] [106]
Donepezil DMIYG7Z Moderate Antagonize the effect of Haloperidol when combined with Donepezil. Alzheimer disease [8A20] [106]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Haloperidol and Metronidazole. Amoebiasis [1A36] [107]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Haloperidol and Isosorbide dinitrate. Anal fissure/fistula [DB50] [108]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Haloperidol and Trimethaphan. Aneurysm/dissection [BD50] [109]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ivabradine. Angina pectoris [BA40] [101]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Haloperidol and Dronedarone. Angina pectoris [BA40] [98]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Haloperidol and Amyl nitrite. Angina pectoris [BA40] [108]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Haloperidol and Nifedipine. Angina pectoris [BA40] [108]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Haloperidol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [98]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Haloperidol and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [98]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Haloperidol and Cilostazol. Arterial occlusive disease [BD40] [98]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Haloperidol and Voriconazole. Aspergillosis [1F20] [98]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Haloperidol and Posaconazole. Aspergillosis [1F20] [98]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Levalbuterol. Asthma [CA23] [110]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Terbutaline. Asthma [CA23] [111]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Pirbuterol. Asthma [CA23] [111]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Salbutamol. Asthma [CA23] [112]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Haloperidol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [98]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Haloperidol and Desipramine. Attention deficit hyperactivity disorder [6A05] [113]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Haloperidol and Ofloxacin. Bacterial infection [1A00-1C4Z] [98]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Haloperidol and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [98]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Haloperidol and Clarithromycin. Bacterial infection [1A00-1C4Z] [98]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Haloperidol and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [98]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Haloperidol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [114]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Haloperidol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [98]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Haloperidol and Norfloxacin. Bacterial infection [1A00-1C4Z] [98]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Haloperidol and Levofloxacin. Bacterial infection [1A00-1C4Z] [98]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Haloperidol and Lomefloxacin. Bacterial infection [1A00-1C4Z] [98]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Haloperidol and Telithromycin. Bacterial infection [1A00-1C4Z] [98]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Haloperidol and Retigabine. Behcet disease [4A62] [98]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Haloperidol and Cariprazine. Bipolar disorder [6A60] [100]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Haloperidol and Loperamide. Bowel habit change [ME05] [115]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Haloperidol and Eribulin. Breast cancer [2C60-2C6Y] [98]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Haloperidol and Lapatinib. Breast cancer [2C60-2C6Y] [98]
Tucatinib DMBESUA Moderate Decreased metabolism of Haloperidol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [116]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Haloperidol and Toremifene. Breast cancer [2C60-2C6Y] [98]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Haloperidol and Bosutinib. Breast cancer [2C60-2C6Y] [98]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Haloperidol when combined with Acetylcholine. Cataract [9B10] [117]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Haloperidol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [98]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Haloperidol and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [118]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Haloperidol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [111]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [110]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Haloperidol and Tiotropium. Chronic obstructive pulmonary disease [CA22] [118]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Haloperidol and Salmeterol. Chronic obstructive pulmonary disease [CA22] [111]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Haloperidol and Revefenacin. Chronic obstructive pulmonary disease [CA22] [118]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Haloperidol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [111]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [111]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Haloperidol and Dihydrocodeine. Chronic pain [MG30] [119]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Haloperidol and Oxaliplatin. Colorectal cancer [2B91] [98]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Isoproterenol. Conduction disorder [BC63] [111]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Haloperidol and Olopatadine. Conjunctiva disorder [9A60] [120]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Haloperidol and Halothane. Corneal disease [9A76-9A78] [98]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Haloperidol and Propofol. Corneal disease [9A76-9A78] [121]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Haloperidol and Sevoflurane. Corneal disease [9A76-9A78] [98]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Haloperidol and Alfentanil. Corneal disease [9A76-9A78] [103]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Haloperidol and Remifentanil. Corneal disease [9A76-9A78] [103]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Haloperidol and Probucol. Coronary atherosclerosis [BA80] [98]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Haloperidol caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [107]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Haloperidol and Clofazimine. Crohn disease [DD70] [98]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Haloperidol and Mifepristone. Cushing syndrome [5A70] [98]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Haloperidol and Pasireotide. Cushing syndrome [5A70] [98]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Haloperidol and Osilodrostat. Cushing syndrome [5A70] [98]
Lumacaftor DMCLWDJ Major Increased metabolism of Haloperidol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [122]
Ivacaftor DMZC1HS Moderate Decreased clearance of Haloperidol due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [123]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Haloperidol and Ethanol. Cystitis [GC00] [120]
MK-8228 DMOB58Q Moderate Decreased metabolism of Haloperidol caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [124]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Haloperidol and Cyclandelate. Dementia [6D80-6D8Z] [108]
Aprepitant DM053KT Moderate Decreased metabolism of Haloperidol caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [125]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Haloperidol and Sertraline. Depression [6A70-6A7Z] [98]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Haloperidol and Trimipramine. Depression [6A70-6A7Z] [113]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Haloperidol and Cyclobenzaprine. Depression [6A70-6A7Z] [100]
Nortriptyline DM4KDYJ Major Decreased metabolism of Haloperidol caused by Nortriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [113]
Paroxetine DM5PVQE Moderate Decreased metabolism of Haloperidol caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [126]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Haloperidol and Escitalopram. Depression [6A70-6A7Z] [98]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Haloperidol and OPC-34712. Depression [6A70-6A7Z] [100]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Haloperidol and Clomipramine. Depression [6A70-6A7Z] [113]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Haloperidol and Trazodone. Depression [6A70-6A7Z] [98]
Amoxapine DMKITQE Major Decreased metabolism of Haloperidol caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [113]
Doxepin DMPI98T Major Decreased metabolism of Haloperidol caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [113]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Haloperidol and Maprotiline. Depression [6A70-6A7Z] [98]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Haloperidol and Nitroglycerin. Diabetic foot ulcer [BD54] [108]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Haloperidol and Mepenzolate. Digestive system disease [DE2Z] [100]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Haloperidol and Oxybutynine. Discovery agent [N.A.] [100]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Haloperidol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [127]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Haloperidol and Meclizine. Dizziness and giddiness [MB48] [100]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Haloperidol and Deutetrabenazine. Dystonic disorder [8A02] [128]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Haloperidol and Ingrezza. Dystonic disorder [8A02] [98]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Haloperidol and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [129]
Primidone DM0WX6I Major Increased metabolism of Haloperidol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [104]
Mephenytoin DM5UGDK Moderate Antagonize the effect of Haloperidol when combined with Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [101]
Cenobamate DMGOVHA Moderate Increased metabolism of Haloperidol caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [130]
Fosphenytoin DMOX3LB Major Increased metabolism of Haloperidol caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [104]
Rufinamide DMWE60C Moderate Increased metabolism of Haloperidol caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Ethotoin DMXWOCP Moderate Antagonize the effect of Haloperidol when combined with Ethotoin. Epilepsy/seizure [8A61-8A6Z] [101]
Phenobarbital DMXZOCG Major Increased metabolism of Haloperidol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [104]
Carbamazepine DMZOLBI Major Increased metabolism of Haloperidol caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [104]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Haloperidol when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [131]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Haloperidol and Guanabenz. Essential hypertension [BA00] [108]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Haloperidol and Ethacrynic acid. Essential hypertension [BA00] [109]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Haloperidol and Phenoxybenzamine. Essential hypertension [BA00] [108]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Haloperidol and Nicardipine. Essential hypertension [BA00] [108]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Haloperidol and Mecamylamine. Essential hypertension [BA00] [108]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Benzthiazide. Essential hypertension [BA00] [107]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Haloperidol and Nadolol. Essential hypertension [BA00] [108]
Tazemetostat DMWP1BH Moderate Increased metabolism of Haloperidol caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [132]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Haloperidol and Solifenacin. Functional bladder disorder [GC50] [98]
Mirabegron DMS1GYT Moderate Decreased metabolism of Haloperidol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [133]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Haloperidol and Tolterodine. Functional bladder disorder [GC50] [100]
Itraconazole DMCR1MV Moderate Decreased metabolism of Haloperidol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [134]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Haloperidol and Pentamidine. Fungal infection [1F29-1F2F] [98]
Terbinafine DMI6HUW Moderate Decreased metabolism of Haloperidol caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [135]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Haloperidol and Ketoconazole. Fungal infection [1F29-1F2F] [98]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Amphotericin B. Fungal infection [1F29-1F2F] [107]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Haloperidol and Phentolamine. Gangrene [MC85] [108]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Haloperidol and Propantheline. Gastric ulcer [DA60] [100]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Haloperidol and Cisapride. Gastro-oesophageal reflux disease [DA22] [98]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Haloperidol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [98]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Acetazolamide. Glaucoma [9C61] [107]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Haloperidol when combined with Isoflurophate. Glaucoma [9C61] [117]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Haloperidol and Carteolol. Glaucoma [9C61] [108]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Haloperidol when combined with Pilocarpine. Glaucoma [9C61] [117]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Haloperidol and Eplerenone. Heart failure [BD10-BD1Z] [108]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Haloperidol and Carvedilol. Heart failure [BD10-BD1Z] [108]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Chlorothiazide. Heart failure [BD10-BD1Z] [107]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Furosemide. Heart failure [BD10-BD1Z] [107]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Haloperidol and Amiloride. Heart failure [BD10-BD1Z] [108]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Bumetanide. Heart failure [BD10-BD1Z] [107]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [107]
Isoniazid DM5JVS3 Minor Decreased metabolism of Haloperidol caused by Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [136]
Rifampin DMA8J1G Major Increased metabolism of Haloperidol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [122]
Rifapentine DMCHV4I Major Increased metabolism of Haloperidol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [104]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Haloperidol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [98]
Cobicistat DM6L4H2 Moderate Decreased clearance of Haloperidol due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [137]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Haloperidol and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [138]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Haloperidol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [139]
Etravirine DMGV8QU Moderate Increased metabolism of Haloperidol caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [140]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Haloperidol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [98]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Haloperidol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [98]
Darunavir DMN3GCH Moderate Decreased metabolism of Haloperidol caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [141]
Ritonavir DMU764S Moderate Decreased metabolism of Haloperidol caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [142]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Haloperidol and Isosorbide mononitrate. Hydrocephalus [8D64] [108]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Haloperidol caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [107]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Haloperidol and Eprosartan. Hypertension [BA00-BA04] [108]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Haloperidol and Acebutolol. Hypertension [BA00-BA04] [108]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Haloperidol and Moexipril. Hypertension [BA00-BA04] [108]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Haloperidol and Bisoprolol. Hypertension [BA00-BA04] [108]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Haloperidol and Captopril. Hypertension [BA00-BA04] [108]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Haloperidol and Penbutolol. Hypertension [BA00-BA04] [108]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Haloperidol and Clonidine. Hypertension [BA00-BA04] [108]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Haloperidol and Losartan. Hypertension [BA00-BA04] [108]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Haloperidol and Nebivolol. Hypertension [BA00-BA04] [108]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Haloperidol and Verapamil. Hypertension [BA00-BA04] [108]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Haloperidol and Pindolol. Hypertension [BA00-BA04] [108]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Haloperidol and Fenoldopam. Hypertension [BA00-BA04] [108]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Indapamide. Hypertension [BA00-BA04] [107]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Haloperidol and Benazepril. Hypertension [BA00-BA04] [108]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Haloperidol and Trichlormethiazide. Hypertension [BA00-BA04] [108]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Haloperidol and Labetalol. Hypertension [BA00-BA04] [108]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Haloperidol and Diazoxide. Hypertension [BA00-BA04] [108]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Haloperidol and Enalapril. Hypertension [BA00-BA04] [108]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Haloperidol and Perindopril. Hypertension [BA00-BA04] [108]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Haloperidol and Quinapril. Hypertension [BA00-BA04] [108]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Haloperidol and Deserpidine. Hypertension [BA00-BA04] [108]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Haloperidol and Telmisartan. Hypertension [BA00-BA04] [108]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Haloperidol and Irbesartan. Hypertension [BA00-BA04] [108]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Haloperidol and Hydralazine. Hypertension [BA00-BA04] [108]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Haloperidol and Lisinopril. Hypertension [BA00-BA04] [108]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydrochlorothiazide. Hypertension [BA00-BA04] [107]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Haloperidol and Clevidipine butyrate. Hypertension [BA00-BA04] [108]
Conivaptan DM1V329 Moderate Decreased metabolism of Haloperidol caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [143]
Givosiran DM5PFIJ Moderate Decreased metabolism of Haloperidol caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [144]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Haloperidol and Belladonna. Infectious gastroenteritis/colitis [1A40] [100]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Haloperidol and Amantadine. Influenza [1E30-1E32] [145]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Haloperidol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [146]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Haloperidol and Propiomazine. Insomnia [7A00-7A0Z] [100]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Haloperidol and ITI-007. Insomnia [7A00-7A0Z] [100]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Haloperidol and Polyethylene glycol. Irritable bowel syndrome [DD91] [98]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Phenolphthalein. Irritable bowel syndrome [DD91] [98]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Haloperidol and Clidinium. Irritable bowel syndrome [DD91] [100]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Haloperidol and Dicyclomine. Irritable bowel syndrome [DD91] [100]
Physostigmine DM2N0TO Moderate Antagonize the effect of Haloperidol when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [106]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Haloperidol and Crizotinib. Lung cancer [2C25] [98]
Brigatinib DM7W94S Moderate Increased metabolism of Haloperidol caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [147]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Haloperidol and Porfimer Sodium. Lung cancer [2C25] [148]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Haloperidol and Ceritinib. Lung cancer [2C25] [98]
PF-06463922 DMKM7EW Moderate Increased metabolism of Haloperidol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [149]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Haloperidol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [150]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Haloperidol and Osimertinib. Lung cancer [2C25] [98]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Haloperidol and Selpercatinib. Lung cancer [2C25] [98]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Haloperidol and Lumefantrine. Malaria [1F40-1F45] [107]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Haloperidol and Halofantrine. Malaria [1F40-1F45] [151]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Haloperidol and Chloroquine. Malaria [1F40-1F45] [98]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Haloperidol and Hydroxychloroquine. Malaria [1F40-1F45] [98]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Haloperidol and Primaquine. Malaria [1F40-1F45] [98]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Haloperidol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [98]
Idelalisib DM602WT Moderate Decreased metabolism of Haloperidol caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [152]
IPI-145 DMWA24P Moderate Decreased metabolism of Haloperidol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [153]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Haloperidol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [154]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Haloperidol and Vemurafenib. Melanoma [2C30] [98]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Haloperidol and LGX818. Melanoma [2C30] [98]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Haloperidol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [101]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Haloperidol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [155]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Haloperidol and Lasmiditan. Migraine [8A80] [156]
Exjade DMHPRWG Moderate Decreased metabolism of Haloperidol caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [157]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Haloperidol and Flibanserin. Mood disorder [6A60-6E23] [158]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Haloperidol and Panobinostat. Multiple myeloma [2A83] [159]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Haloperidol and Thalidomide. Multiple myeloma [2A83] [160]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Siponimod. Multiple sclerosis [8A40] [107]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Fingolimod. Multiple sclerosis [8A40] [98]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ozanimod. Multiple sclerosis [8A40] [161]
Rifabutin DM1YBHK Major Increased metabolism of Haloperidol caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [104]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Haloperidol and Romidepsin. Mycosis fungoides [2B01] [98]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Haloperidol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [101]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Haloperidol and Nilotinib. Myeloproliferative neoplasm [2A20] [98]
Imatinib DM7RJXL Moderate Decreased metabolism of Haloperidol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [162]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Haloperidol and Dasatinib. Myeloproliferative neoplasm [2A20] [98]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Haloperidol when combined with Dextroamphetamine. Narcolepsy [7A20] [163]
Modafinil DMYILBE Minor Increased metabolism of Haloperidol caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [164]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Haloperidol and Phenindamine. Nasopharyngitis [CA00] [100]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Haloperidol and Dimenhydrinate. Nausea/vomiting [MD90] [100]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Haloperidol and Promethazine. Nausea/vomiting [MD90] [98]
Rolapitant DM8XP26 Moderate Decreased metabolism of Haloperidol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [165]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Haloperidol and Cyclizine. Nausea/vomiting [MD90] [100]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Haloperidol and Metoclopramide. Nausea/vomiting [MD90] [166]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Haloperidol and Granisetron. Nausea/vomiting [MD90] [98]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Haloperidol and Dolasetron. Nausea/vomiting [MD90] [98]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Haloperidol and Ondansetron. Nausea/vomiting [MD90] [98]
Bupropion DM5PCS7 Major Decreased metabolism of Haloperidol caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [98]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Haloperidol and Entrectinib. Non-small cell lung cancer [2C25] [98]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Haloperidol when combined with Phendimetrazine. Obesity [5B80-5B81] [163]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Haloperidol when combined with Amfepramone. Obesity [5B80-5B81] [163]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Haloperidol caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [167]
Benzphetamine DMIJATC Moderate Antagonize the effect of Haloperidol when combined with Benzphetamine. Obesity [5B80-5B81] [163]
Mazindol DMZ36RN Moderate Antagonize the effect of Haloperidol when combined with Mazindol. Obesity [5B80-5B81] [163]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Metolazone. Oedema [MG29] [107]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Polythiazide. Oedema [MG29] [107]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Haloperidol and Levomethadyl Acetate. Opioid use disorder [6C43] [101]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Haloperidol and Lofexidine. Opioid use disorder [6C43] [98]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Haloperidol and Apraclonidine. Optic nerve disorder [9C40] [168]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Haloperidol and Rucaparib. Ovarian cancer [2C73] [98]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Haloperidol and Pentazocine. Pain [MG30-MG3Z] [103]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Haloperidol and Dextropropoxyphene. Pain [MG30-MG3Z] [169]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Haloperidol and Butorphanol. Pain [MG30-MG3Z] [103]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Haloperidol and Oxymorphone. Pain [MG30-MG3Z] [103]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Haloperidol and Levorphanol. Pain [MG30-MG3Z] [103]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Haloperidol and Dezocine. Pain [MG30-MG3Z] [103]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Haloperidol and Flavoxate. Pain [MG30-MG3Z] [100]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Haloperidol and Nalbuphine. Pain [MG30-MG3Z] [103]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Haloperidol when combined with Methamphetamine. Pain [MG30-MG3Z] [170]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Haloperidol and Buprenorphine. Pain [MG30-MG3Z] [98]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Haloperidol and Hydrocodone. Pain [MG30-MG3Z] [103]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Haloperidol and Triclabendazole. Parasitic worm infestation [1F90] [98]
Pergolide DM14MAE Moderate Antagonize the effect of Haloperidol when combined with Pergolide. Parkinsonism [8A00] [171]
Opicapone DM1BKA6 Moderate Antagonize the effect of Haloperidol when combined with Opicapone. Parkinsonism [8A00] [171]
Biperiden DME78OA Moderate Antagonize the effect of Haloperidol when combined with Biperiden. Parkinsonism [8A00] [131]
Levodopa DMN3E57 Moderate Antagonize the effect of Haloperidol when combined with Levodopa. Parkinsonism [8A00] [171]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Haloperidol and Pimavanserin. Parkinsonism [8A00] [98]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Haloperidol when combined with Bromocriptine. Parkinsonism [8A00] [171]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Haloperidol and Orphenadrine. Parkinsonism [8A00] [100]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Haloperidol and Apomorphine. Parkinsonism [8A00] [98]
Abametapir DM2RX0I Moderate Decreased metabolism of Haloperidol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [172]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Haloperidol and Methylscopolamine. Peptic ulcer [DA61] [100]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Haloperidol and Famotidine. Peptic ulcer [DA61] [107]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Haloperidol and Macimorelin. Pituitary gland disorder [5A60-5A61] [173]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Haloperidol and Lefamulin. Pneumonia [CA40] [174]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Hydrocortisone. Postoperative inflammation [1A00-CA43] [107]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Haloperidol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [175]
Ritodrine DM4V6RL Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Ritodrine. Preterm labour/delivery [JB00] [111]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Haloperidol and Degarelix. Prostate cancer [2C82] [98]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Haloperidol and ABIRATERONE. Prostate cancer [2C82] [98]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Haloperidol and Nilutamide. Prostate cancer [2C82] [98]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Haloperidol and Enzalutamide. Prostate cancer [2C82] [98]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Haloperidol and Relugolix. Prostate cancer [2C82] [98]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Haloperidol and Bicalutamide. Prostate cancer [2C82] [98]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Haloperidol and Terazosin. Prostate hyperplasia [GA90] [108]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Haloperidol and Tamsulosin. Prostate hyperplasia [GA90] [108]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Haloperidol and Silodosin. Prostate hyperplasia [GA90] [108]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Haloperidol and Levomepromazine. Psychotic disorder [6A20-6A25] [98]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Haloperidol and Fluphenazine. Psychotic disorder [6A20-6A25] [98]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Haloperidol and Triflupromazine. Psychotic disorder [6A20-6A25] [98]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Haloperidol and Tolazoline. Pulmonary hypertension [BB01] [108]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Haloperidol and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [176]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Haloperidol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [98]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Haloperidol and Neupro. Restless legs syndrome [7A80] [171]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Haloperidol and Fentanyl. Sensation disturbance [MB40] [103]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Haloperidol and Sufentanil. Sensation disturbance [MB40] [103]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Haloperidol and Vardenafil. Sexual dysfunction [HA00-HA01] [98]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Haloperidol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [177]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Haloperidol caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [101]
Larotrectinib DM26CQR Moderate Decreased metabolism of Haloperidol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [107]
Armodafinil DMGB035 Minor Increased metabolism of Haloperidol caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [164]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Haloperidol and LEE011. Solid tumour/cancer [2A00-2F9Z] [98]
Cisplatin DMRHGI9 Moderate Increased risk of ventricular arrhythmias by the combination of Haloperidol and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [107]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Haloperidol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [98]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Haloperidol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [98]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Haloperidol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [98]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Haloperidol and Pitolisant. Somnolence [MG42] [98]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Haloperidol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [98]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Haloperidol and Adenosine. Supraventricular tachyarrhythmia [BC81] [178]
Fostamatinib DM6AUHV Moderate Decreased clearance of Haloperidol due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [179]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Haloperidol and Lenvatinib. Thyroid cancer [2D10] [98]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Haloperidol and Cabozantinib. Thyroid cancer [2D10] [98]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Haloperidol and Papaverine. Tonus and reflex abnormality [MB47] [180]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Haloperidol and Tizanidine. Tonus and reflex abnormality [MB47] [98]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Haloperidol and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [176]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Haloperidol and Tacrolimus. Transplant rejection [NE84] [98]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Haloperidol and Atropine. Unspecific substance harmful effect [NE6Z] [100]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Haloperidol and Astemizole. Vasomotor/allergic rhinitis [CA08] [98]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Haloperidol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [100]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Haloperidol and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [100]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Haloperidol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [98]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Haloperidol and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [100]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Haloperidol and Acrivastine. Vasomotor/allergic rhinitis [CA08] [100]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Haloperidol and Azatadine. Vasomotor/allergic rhinitis [CA08] [100]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Haloperidol and Procainamide. Ventricular tachyarrhythmia [BC71] [98]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Haloperidol and Propafenone. Ventricular tachyarrhythmia [BC71] [98]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Haloperidol and Flecainide. Ventricular tachyarrhythmia [BC71] [98]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Haloperidol and Amiodarone. Ventricular tachyarrhythmia [BC71] [98]
⏷ Show the Full List of 329 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Lactic acid E00020 612 Acidulant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Brushite E00392 104805 Diluent
Calcium stearate E00244 15324 lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Haloperidol 10 mg tablet 10 mg Oral Tablet Oral
Haloperidol 20 mg tablet 20 mg Oral Tablet Oral
Haloperidol 0.5 mg tablet 0.5 mg Oral Tablet Oral
Haloperidol 1 mg tablet 1 mg Oral Tablet Oral
Haloperidol 2 mg tablet 2 mg Oral Tablet Oral
Haloperidol 5 mg tablet 5 mg Oral Tablet Oral
Haloperidol Decanoate eq 50mg base/ml injectable eq 50mg base/ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
8 Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
9 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
10 Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
11 Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
12 In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
13 Drug Interactions Flockhart Table
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
25 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
26 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
27 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
28 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
29 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
31 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
32 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
33 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
34 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
35 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
36 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
37 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
38 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
39 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
40 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
41 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
42 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
43 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
44 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
45 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
46 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
47 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
48 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
49 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
50 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
51 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
52 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
53 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
54 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
55 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
56 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
57 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
58 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
59 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
60 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
61 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
62 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
63 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
64 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
65 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
66 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
67 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
68 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
69 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
70 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
71 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
72 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
73 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
74 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
75 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
76 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
77 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
78 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
79 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
80 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
81 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
82 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
83 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
84 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
85 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
86 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
87 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
88 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
89 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
90 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
91 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
92 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
93 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
94 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
95 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
96 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
97 Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
98 Canadian Pharmacists Association.
99 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
100 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
101 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
102 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
103 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
104 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
105 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
106 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
107 Cerner Multum, Inc. "Australian Product Information.".
108 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
109 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
110 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
111 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
112 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
113 Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
114 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
115 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
116 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
117 Multum Information Services, Inc. Expert Review Panel.
118 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
119 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
120 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
121 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
122 Cerner Multum, Inc "ANVISA Bulario Eletrnico." .
123 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
124 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
125 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
126 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
127 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
128 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
129 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
130 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
131 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
132 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
133 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
134 Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, Kaneko S, Inoue Y "Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism." J Clin Psychopharmacol 19 (1999): 149-54. [PMID: 10211916]
135 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
136 Takeda M, Nishinuma K, Yamashita S, et al "Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis." Clin Neuropharmacol 9 (1986): 386-97. [PMID: 3731135]
137 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
138 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
139 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
140 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
141 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
142 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
143 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
144 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
145 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
146 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
147 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
148 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
149 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
150 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
151 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
152 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
153 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
154 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
155 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
156 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
157 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
158 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
159 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
160 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
161 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
162 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
163 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
164 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
165 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
166 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
167 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
168 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
169 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
170 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
171 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
172 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
173 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
174 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
175 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
176 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
177 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
178 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
179 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
180 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]